Takeda Paves The Way For Myovant With Phase III Fibroid Success
Executive Summary
Takeda has reported the first in a wave of Phase III trials to support the potential uterine fibroid therapy relugolix. The news is good for licensee Myovant, which earlier this year started two larger Phase III studies of the product.
You may also be interested in...
Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.
Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight
Axovant was Roivant's star and the first test of its risk-reducing strategy, but the company will attempt to move its spotlight to other assets at an R&D day on July 10. Ahead of the event, Roivant announced a reorganization to strengthen its subsidiaries and accelerate the creation of new ones.
Pregnant Pause: First Phase III Data Hint At Improved Success For ObsEva IVF Drug
Top-line data for the IVF drug look promising but what investors really want to see are the Phase III data for ObsEva's lead product expected later this year in the much larger uterine fibroid market.